Navigation Links
Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
Date:10/2/2008

STOCKHOLM, October 2 /PRNewswire/ -- Athera Biotechnologies AB and Dyax Corp. (NASDAQ:DYAX) announced today that they have entered into a collaboration to discover and to develop therapeutic products for the prevention or treatment of cardiovascular inflammatory diseases.

The collaboration follows the recent publication of work by Athera scientific founders, Professors Frostegard and de Faire of the Karolinska Institutet. The research links naturally occurring antibodies against phosphorylcholine (PC) to atherosclerosis, and correlates low antibody levels with an increased risk of developing cardiovascular disease. Atherosclerosis is a chronic inflammatory disease in which the walls of the blood vessels are thickened and become less elastic.

During the discovery phase of the collaboration, Dyax will utilize its proprietary antibody libraries to generate fully human monoclonal antibodies. Athera will provide reagents, assays, and in vivo animal models for use in selecting a clinical product candidate. Upon successful completion of the discovery work, Athera and Dyax will have the option to advance the antibody lead(s) into clinical development under the terms of a global co-development and commercialization agreement.

"We are very pleased to be working with Athera," commented Clive Wood, EVP, Discovery Research and CSO of Dyax Corp. "Through their innovative research from the Karolinska Institutet, we believe Athera has identified an exciting potential opportunity for therapeutic antibody treatment of cardiovascular inflammation."

"The strength of Dyax's phage display technology, screening capabilities and expertise in drug discovery make them an excellent partner to advance our cardiovascular research program,"
'/>"/>

SOURCE Athera Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
2. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... According to a new market research report ... Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices (Mapping, Recording, ... Global Forecasts to 2019 ", published by MarketsandMarkets, the Electrophysiology ... by 2019 with a CAGR of around 10.3% during ... Browse   90   ma rket data T ...
(Date:3/27/2015)... 2015   Hospira, Inc. (NYSE: ... the world,s leading provider of injectable drugs and ... evaluation of biosimilarity of its proposed biosimilar, Epoetin ... (FDA) conditionally approved name of RETACRIT™, compared to ... study data were presented at the National Kidney ...
(Date:3/27/2015)... , March 27, 2015 ... 2015" therapeutic market research report of 52 pages ... online business intelligence library. The report ... on the therapeutic development for Visceral Pain, complete ... by drug target, mechanism of action (MoA), route ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... a world-leading developer and marketer of innovative medical technologies ... Ltd, a wholly-owned subsidiary of ConvaTec Holdings UK Ltd, ... a UK-based company that specialises in the discreet home ... As a well-respected company in the home ...
... President and CEO Randall Moreadith, MD, PhD, reported today that ... advance its lead oncology candidate SER-203 into a Phase I ... pleased to report to our existing and new shareholders the ... 2010. This is a very significant milestone for Serina Therapeutics, ...
Cached Medicine Technology:ConvaTec Announces Acquisition of Trent Direct 2Serina Therapeutics, Inc. Closes $9.5 Million Financing Round 2
(Date:3/28/2015)... 28, 2015 Designers and Professionals of ... entitled Scratches 5K from Pixel Film Studios. , “Scratches ... any media inside Final Cut Pro X” Said Christina ... time and is an effective tool for any FCPX ... Scratches 5K's intuitive grunge overlays. Simply drag title layers ...
(Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
(Date:3/27/2015)... Island, NY (PRWEB) March 27, 2015 ... cancer-focused training and business criteria for the spa and ... services to clients who have experienced or are living ... the global Spafinder Wellness 365® Network, will be identified ... and recognized as a provider of safe, therapeutic services ...
(Date:3/27/2015)... The federal court overseeing thousands of ... medication increases the risk that a patient will develop ... Dismiss four individual cases that had been filed in ... in the U.S. District Court, District of South Carolina, ... were warranted because the plaintiffs in those claims had ...
(Date:3/27/2015)... March 27, 2015 Top medical tourism ... patients travel to the Dominican Republic to benefit from ... clinic is turning the medical tourism industry upside-down and ... — with trustworthy services becoming the central influence. ... plastic surgeon. Patients are not only attracted to low-cost ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 2Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 3
... many as 178 newborn babies died at a government-run ... Amar Agrawal told the state assembly Tuesday . ... about the lack of basic medical facilities at the ... reported 424 deaths of newly born babies in 2006 ...
... bird flu antibodies in migrant birds in five Siberian regions, ... ,"Out of over 4,000 samples taken in the ... to contain genetic material of the A-H5 virus and antibodies ... spokesman said the presence of antibodies meant that either the ...
... two studies indicate that elevated nonfasting triglyceride levels ... heart attack , with one study finding that ... this association. ,Triglyceride levels are usually ... certain types of lipoprotein particles (remnant lipoproteins), a ...
... patients a short course of corticosteroids after they have been ... of a relapse, a Cochrane Systematic Review has found. ... benefit lasts for about three weeks. ,This updated ... together involved 374 people. ,,Between 12% and 16% of ...
... is a more effective way of losing weight after pregnancy ... during pregnancy and many gradually lose it afterwards, but some ... retained body weight may be one factor that contributes to ... of returning to, and maintaining, pre-pregnant weights, and there is ...
... (saline) into your nose can help reduce the symptoms ... of the nasal passages. , ,Between 5% and ... passages (chronic rhinosinusitis). Many homoeopathic and yogic forms of ... symptoms, and it is now often recommended as part ...
Cached Medicine News:Health News:High Nonfasting Triglyceride Levels Linked With Cardiovascular Risks 2
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride, 10mM Magnesium Chloride, 10mM Mag. Sulfate....
Innovative hemi device combining anatomic design with the advanced material pyrocarbon....
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
Medicine Products: